Podrobno

Effective targeting of E2F1 transcription factor via siRNA gene electrotransfer in HT-29 colorectal carcinoma xenografts
ID Jesenko, Tanja (Avtor), ID Kranjc Brezar, Simona (Avtor), ID Pišljar, Živa (Avtor), ID Božič, Tim (Avtor), ID Markelc, Boštjan (Avtor), ID Cazzato, Monica (Avtor), ID Grassi, Gabriele (Avtor), ID Čemažar, Maja (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (4,40 MB)
MD5: D3BF949517000A3A0EE3C24A8DD1A7E8
URLURL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S1567539425000970 Povezava se odpre v novem oknu

Izvleček
Colorectal cancer (CRC) remains a significant global health concern, with survival outcomes heavily dependent on the stage at diagnosis. Targeted therapies offer a promising approach to improve patient outcomes, particularly by addressing molecular drivers of tumor progression. One such target is the E2F1 transcription factor, a key regulator of the cell cycle and a contributor to proliferation, differentiation, apoptosis, metastasis, and chemoresistance in CRC. Previous studies have demonstrated the efficacy of E2F1 silencing via siRNA-loaded nanoliposomes in reducing tumor cell growth, but challenges such as immunogenicity and off-target effects have limited their in vivo application. In this study, we evaluated the potential of gene electrotransfer (GET) as a non-viral delivery system for delivery of therapeutic siRNA targeting E2F1 in the HT-29 CRC model. In vitro experiments showed effective silencing of E2F1 expression and a significant reduction in HT-29 cell survival. Subsequent in vivo studies confirmed the therapeutic potential of siE2F1 GET, with results demonstrating tumor growth delay, decreased proliferation, and increased necrosis in the tumors. This study establishes proof-of-principle for targeting E2F1 in CRC using GET, showcasing its versatility and therapeutic potential.

Jezik:Angleški jezik
Ključne besede:colorectal carcinoma, E2F1, gene electrotransfer, GET, silencing, siRNA
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
BF - Biotehniška fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:10 str.
Številčenje:Vol. 165, art. 108994
PID:20.500.12556/RUL-169105 Povezava se odpre v novem oknu
UDK:616-006
ISSN pri članku:1567-5394
DOI:10.1016/j.bioelechem.2025.108994 Povezava se odpre v novem oknu
COBISS.SI-ID:235435267 Povezava se odpre v novem oknu
Datum objave v RUL:12.05.2025
Število ogledov:333
Število prenosov:127
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Bioelectrochemistry
Založnik:Elsevier
ISSN:1567-5394
COBISS.SI-ID:2502484 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:kolorektalni rak, E2F1, GET, elektroprenos genov

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0003
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Financer:MAECI - Italy, Ministry of Foreign Affairs and International Cooperation
Številka projekta:VN21GR01

Financer:Lega Italiana per la Lotta Contro I Tumori
Naslov:Evaluation of a novel antifibrotic and antitumor molecule for hepatocellular carcinoma

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj